Montelukast Sandoz

Montelukast, the active ingredient in Montelukast Sandoz, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It selectively blocks cysteinyl leukotriene receptors, helping to reduce bronchoconstriction and airway inflammation. The medication is indicated for maintenance therapy of asthma, prevention of exercise‑induced bronchoconstriction, and relief of allergic rhinitis in both adult and pediatric patients.

GNH USA supplies Montelukast Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control respiratory and allergic conditions.

- Asthma: Improves long‑term control of symptoms and reduces the frequency of exacerbations. - Exercise‑induced bronchoconstriction: Prevents narrowing of airways triggered by physical activity. - Allergic rhinitis: Alleviates nasal congestion, sneezing and itching associated with seasonal allergies.

Montelukast may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort or cramping. - Cough: transient irritation of the throat. - Dyspepsia: indigestion or upset stomach.

Serious or Rare Side Effects: - Mood changes or suicidal thoughts: monitor for depression or anxiety. - Angioedema: swelling of face, lips, tongue, or throat. - Anaphylaxis: severe allergic reaction requiring immediate medical attention.

Before prescribing Montelukast, clinicians should consider several safety measures.

- Assess asthma control before initiating: ensure patient is on appropriate inhaled therapy. - Monitor for neuropsychiatric events: watch for mood changes, depression, or suicidal thoughts. - Use with caution in hepatic impairment: adjust therapy if liver function is compromised. - Avoid in patients with known hypersensitivity to montelukast or any excipients. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Montelukast can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Phenobarbital, rifampin, carbamazepine: may markedly reduce montelukast plasma concentrations. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase montelukast exposure and risk of adverse effects.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR; monitor coagulation parameters. - Theophylline: additive bronchial effects; observe for changes in respiratory status. - Epinephrine: may diminish the acute relief provided by epinephrine in severe asthma attacks; monitor response.